The Drugs Controller General of India (DCGI) approved Biological E Limited’s Corbevax vaccine for restricted use in an emergency in youngsters aged 12 to less than 18 years.
The vaccine is India’s first indigenously developed Receptor Binding Domain (RBD) protein subunit vaccine against Covid-19.
As per reports, the Corbevax vaccine is administered via an intramuscular route with two doses set 28 days apart and is stored at 2 to 8 degrees Celsius.
Till now India has been providing Bharat Biotech’s Covaxin to teens between 15 and 18 years old since January 3.
Mahima Datla, managing director, Biological E. Limited, said, “We are pleased with this momentous development, which helps extend the reach of our vaccine to the age group of 12 to 18 years in our country. We truly believe that with this approval, we are even closer to achieving our global fight against the pandemic. Once fully immunized, children can resume their activities and educational pursuits in schools and colleges with no apprehension.”